Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. Rajiv Gandhi and other management representatives referred to debt repayment, indicating existing debt reduction efforts (e.g., Rs. 25-30 crores being paid annually, and Rs. 30 crores debt reduced recently). Management emphasized focusing on improving profitability and operational performance rather than new fundraising. No explicit plans or discussions about raising fresh capital via debt or equity were disclosed during the call.

Any current/future capex/capital investment/strategic investment?

Rs. 168 crores of capital work-in-progress primarily related to: - BSL-3 facility at Hester India plant (originally for COVID vaccine production, now being repurposed for veterinary vaccines). - Fill-finish line, expected to be commercially operational within the next two months. Completed receipt of all government grants for building BSL-3 facility; no pending grants. Repurposing BSL-3 facility for commercial production of veterinary vaccines to enhance manufacturing capacity. Active steps to introduce new products in therapeutics, supplements, prescription, and pet food diet segments to

Future growth expectations in sales/revenue/volumes?

The poultry industry is on an upswing, leading to increased vaccine uptake as farmers adopt more progressive farming methods. Animal healthcare industry growth is expected around 8%-9%, with Hester Biosciences targeting 12% standalone growth. For FY25 and beyond, the company aims to improve both topline (sales/revenue) and bottomline (profitability), working hard to capitalize on market recovery and election year demand. The African subsidiary loss is expected to improve with gradual market normalization, enabling better order fulfillment and revenue generation. New product introductio

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is optimistic about growth, aiming to reach Rs. 300 crores in size this year and beyond, with strategic focus refined through recent insights. Animal Health division expects stable profitability with improved topline and focus on bottomline profitability. The poultry healthcare segment is on an upswing, with expected continued improvement driven by industry recovery and new product introductions. Overall growth in the animal healthcare industry is around 8-9%; Hester Biosciences has grown at about 12% standalone. The company is targeting top-line and bottom-line improvement

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a quantified current or expected orderbook or pending orders. Rajiv Gandhi noted that tenders won in Tanzania could not be supplied due to foreign exchange issues, implying some pending orders. There is an anticipation of government orders for Hester Africa in the upcoming financial year, focused on East and Central African countries. The company is building a robust marketing network in African regions to support future orders. No government grants are pending; all grants related to the BSL-3 facility have been received. The repurposed BSL-3 facility

IN US

Sale is live|00:00:00left today

Hester Biosciences LtdQ1 FY24Pharmaceuticals & Biotechnology

Hester Biosciences Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,953P/E: 38.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The poultry industry is on an upswing, leading to increased vaccine uptake as farmers adopt more progressive farming methods.
→Animal healthcare industry growth is expected around 8%-9%, with Hester Biosciences targeting 12% standalone growth.
→For FY25 and beyond, the company aims to improve both topline (sales/revenue) and bottomline (profitability), working hard to capitalize on market recovery and election year demand.
→The African subsidiary loss is expected to improve with gradual market normalization, enabling better order fulfillment and revenue generation.
→New product introductions in therapeutics, supplements, pet food diet segments, and specialized poultry products are anticipated to contribute to growth.
→The BSL-3 facility and fill-finish line are nearing commercialization, expected to enhance manufacturing capacity and sales in the near term.
→Distribution network expansion and improved after-sales monitoring aim to strengthen market position and volume growth.

Margin guidance

Category 3

→The company is optimistic about growth, aiming to reach Rs. 300 crores in size this year and beyond, with strategic focus refined through recent insights.
→Animal Health division expects stable profitability with improved topline and focus on bottomline profitability.
→The poultry healthcare segment is on an upswing, with expected continued improvement driven by industry recovery and new product introductions.
→Overall growth in the animal healthcare industry is around 8-9%; Hester Biosciences has grown at about 12% standalone.
→The company is targeting top-line and bottom-line improvements, albeit cautiously due to market uncertainties.
→EBITDA and PAT missed growth slightly but showed positive trends; debt reduction by Rs. 30 crores strengthens financial health.
→African subsidiary losses are expected to improve as macro conditions normalize, with confidence to return to profitability within the year.
→Focus on complementing vaccines with health products may affect margin mix but is seen as strategic for long-term growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→Rajiv Gandhi and other management representatives referred to debt repayment, indicating existing debt reduction efforts (e.g., Rs. 25-30 crores being paid annually, and Rs. 30 crores debt reduced recently).
→Management emphasized focusing on improving profitability and operational performance rather than new fundraising.
→No explicit plans or discussions about raising fresh capital via debt or equity were disclosed during the call.

Order book

→The transcript does not explicitly mention a quantified current or expected orderbook or pending orders.
→Rajiv Gandhi noted that tenders won in Tanzania could not be supplied due to foreign exchange issues, implying some pending orders.
→There is an anticipation of government orders for Hester Africa in the upcoming financial year, focused on East and Central African countries.
→The company is building a robust marketing network in African regions to support future orders.
→No government grants are pending; all grants related to the BSL-3 facility have been received.
→The repurposed BSL-3 facility and fill-finish line are expected to go on stream soon, potentially supporting increased order fulfillment.
→Overall, management expresses optimism regarding order inflows as markets recover, though no specific orderbook value is disclosed.

Capex plans

Yes

→Rs. 168 crores of capital work-in-progress primarily related to:
→ - BSL-3 facility at Hester India plant (originally for COVID vaccine production, now being repurposed for veterinary vaccines).
→ - Fill-finish line, expected to be commercially operational within the next two months.
→Completed receipt of all government grants for building BSL-3 facility; no pending grants.
→Repurposing BSL-3 facility for commercial production of veterinary vaccines to enhance manufacturing capacity.
→Active steps to introduce new products in therapeutics, supplements, prescription, and pet food diet segments to diversify offerings.
→Strategic focus on strengthening presence in African veterinary markets with dossiers submitted for additional products (CCPP and Sheep and Goat Pox).
→Ongoing efforts to build a robust marketing network in East and Central Africa to support growth.
→Investment aimed at expanding capacities and market reach, signaling commitment to sustained growth.

How does Hester Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hester Biosciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hester Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio